Biography

Dr. Folu Olugbosi joined TB Alliance as Senior Director, Clinical Development and works on the clinical development of products in the TB Alliance portfolio. He is currently Medical Lead for the NC009 study and Heads the South Africa office.
He obtained his medical degree at the College of Medicine, University of Lagos, Nigeria and specialized in Clinical Microbiology with primary interest in antimicrobial resistance, he worked on Methicillin-Resistant Staphylococcus aureus at the Otto von Guericke University, Magdeburg, Germany. He also obtained a Masters degree (cum-laude) at the University of Siena, Italy in the field of Vaccinology and Pharmaceutical Clinical Development.

Expertise

TB Diagnostics
Public Health

Key Impacts

Safety and efficacy of TBAJ-876 In combination with pretomanid and linezolid: Week 8 analysis result of NC-009

TBAJ-876 in combination with Pa-L demonstrated dose-dependent efficacy. The 100mg TBAJ-876PaL arm had higher 8-week sputum conversion than BPaL and HRZE, which were comparable, and a favorable safety profile compared with HRZE.

Source: Conference 2024

Research Summaries

PAPER
New analysis compares liver safety of TB regimens
23 Mar 2025